ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
August 26, 2021Agios Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for mitapivat for the treatment of adults with pyruvate kinase (PK) deficiency. -
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia
June 18, 2020Agios Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase-R (PKR) activator mitapivat for the treatment of patients with thalassemia.
Pharma Sources Insight January 2025
